Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp 10-K filed Aug 24, 2026
What changed
Item 7, Management’s Discussion and Analysis, against the 10-K filed Aug 22, 2025: 16 added · 18 removed · 50 modified; 4 with only figures updated; 1 moved without change
84 more changes in this Item, word by word, in Powerpack.
Powerpack